NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
Clinical Trials
39 trialsNCT05340413 2026-03-16
RADIOLA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT03025035 2026-02-06
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03516812 2025-09-29
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
University of Washington
Phase 2 Completed
NCT03561870 2025-09-12
OLAGLI
Hospices Civils de Lyon
Phase 2 Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01078662 2025-08-13
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
AstraZeneca
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT04306367 2025-02-17
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Georgetown University
Phase 2 Completed
NCT00753545 2025-02-03
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
AstraZeneca
Phase 2 Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT03233204 2024-12-11
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03745950 2024-12-04
UTOLA
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT03838744 2024-12-04
TOMAS2
Italian Sarcoma Group
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT03205761 2024-10-18
COMETABreast
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT02677038 2024-10-01
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT03127215 2024-05-08
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
Phase 2 Completed
NCT03117933 2024-01-23
OCTOVA
University of Oxford
Phase 2 Completed
NCT00494234 2024-01-19
ICEBERG 1
AstraZeneca
Phase 2 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT03448718 2023-11-22
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Hoosier Cancer Research Network
Phase 2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT04166435 2023-09-06
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
Phase 2 Completed
NCT04669002 2023-08-02
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
Ellipses Pharma
Phase 2 Completed
NCT01063517 2023-07-20
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00679783 2023-07-12
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
AstraZeneca
Phase 2 Completed
NCT04417192 2023-07-06
OLAPem
National Cancer Center Hospital East
Phase 2 Completed
NCT02511223 2023-04-19
10
Sheba Medical Center
Phase 2 Completed
NCT03434158 2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03470805 2022-09-23
Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT03531840 2021-04-09
Olaparib in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03009682 2021-02-18
SUKSES-B
Samsung Medical Center
Phase 2 Completed
NCT03534492 2020-04-06
NEODURVARIB
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02882308 2020-02-07
OPHELIA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT00628251 2019-12-05
ICEBERG 3
AstraZeneca
Phase 2 Completed
NCT00912743 2016-11-09
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
AstraZeneca
Phase 2 Completed